Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad095 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift The Oncologist, 2023. Verfasst von Damien Pouessel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Re-gaud, Toulouse, France. Hauptthemen laut MEDLINE: Glioblastoma, Re-Irradiation, Brain Neoplasms, Radiosurgery. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institut Claudius Regaud, ARC Foundation.
Abstract (Originalsprache)
Background
Hypofractionated stereotactic radiotherapy (hFSRT) is a salvage option for recurrent glioblastoma (GB) which may synergize anti-PDL1 treatment. This phase I study evaluated the safety and the recommended phase II dose of anti-PDL1 durvalumab combined with hFSRT in patients with recurrent GB.
Methods
Patients were treated with 24 Gy, 8 Gy per fraction on days 1, 3, and 5 combined with the first 1500 mg Durvalumab dose on day 5, followed by infusions q4weeks until progression or for a maximum of 12 months. A standard 3 + 3 Durvalumab dose de-escalation design was used. Longitudinal lymphocytes count, cytokines analyses on plasma samples, and magnetic resonance imaging (MRI) were collected.
Results
Six patients were included. One dose limiting toxicity, an immune-related grade 3 vestibular neuritis related to Durvalumab, was reported. Median progression-free interval (PFI) and overall survival (OS) were 2.3 and 16.7 months, respectively. Multi-modal deep learning-based analysis including MRI, cytokines, and lymphocytes/neutrophil ratio isolated the patients presenting pseudoprogression, the longest PFI and those with the longest OS, but statistical significance cannot be established considering phase I data only.
Conclusion
Combination of hFSRT and Durvalumab in recurrent GB was well tolerated in this phase I study. These encouraging results led to an ongoing randomized phase II. (ClinicalTrials.gov Identifier: NCT02866747).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Re-gaud, Toulouse, France.
- Department of Engineering and Medical Physics, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
- INSERM UMR1037, Centre de Recherche en Cancérologie de Toulouse (CRCT), Team Radiation Optimization "RADOPT", Toulouse, France.
- Department of Radiation Oncology, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
- Department of Radiation Oncology, Institut de Cancérologie de l'Ouest, Nantes, France.
- Department of Biostatistics, Institut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
Förderung
- Institut Claudius Regaud
- ARC Foundation
Zitieren
APA
Pouessel, D., Ken, S., Gouaze-Andersson, V., Piram, L., Mervoyer, A., Larrieu-Ciron, D., Cabarrou, B., Lusque, A., Robert, M., Frenel, J. S., Uro-Coste, E., Olivier, P., Mounier, M., Sabatini, U., Sanchez, E. H., Zouitine, M., Berjaoui, A., & Cohen-Jonathan Moyal, E. (2023). Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. The Oncologist. https://doi.org/10.1093/oncolo/oyad095
Vancouver
Pouessel D, Ken S, Gouaze-Andersson V, Piram L, Mervoyer A, Larrieu-Ciron D, et al. Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results. The Oncologist. 2023. doi:10.1093/oncolo/oyad095
BibTeX
@article{Pouessel2023,
author = {Pouessel, Damien and Ken, Soléakhéna and Gouaze-Andersson, Valérie and Piram, Lucie and Mervoyer, Augustin and Larrieu-Ciron, Delphine and Cabarrou, Bastien and Lusque, Amélie and Robert, Marie and Frenel, Jean-Sebastien and Uro-Coste, Emmanuelle and Olivier, Pascale and Mounier, Muriel and Sabatini, Umberto and Sanchez, Eduardo Hugo and Zouitine, Mehdi and Berjaoui, Ahmad and Cohen-Jonathan Moyal, Elizabeth},
title = {Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad095}
}
EUVIMED